An update on current management of advanced renal cell cancer, biomarkers, and future directions.

W. Zhi, Jenny J. Kim
{"title":"An update on current management of advanced renal cell cancer, biomarkers, and future directions.","authors":"W. Zhi, Jenny J. Kim","doi":"10.7243/2049-7962-3-8","DOIUrl":null,"url":null,"abstract":"In the past decade, metastatic renal cell carcinoma (mRCC) treatment underwent significant advancement that resulted in an unprecedented improvement in the prognosis of this disease. This review will provide an updated review of currently approved treatment options, namely antiangiogenic and immunotherapy, as well as treatment guideline recommended by the National Comprehensive Cancer Network (NCCN). We will summarize studies ongoing in determining prognostic and predictive biomarkers in maximizing therapeutic benefit in the treatment of this disease. Lastly, we will discuss promising agents in clinical testing.","PeriodicalId":90787,"journal":{"name":"Annals of cancer research","volume":"29 1","pages":"1-10"},"PeriodicalIF":0.0000,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of cancer research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7243/2049-7962-3-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 7

Abstract

In the past decade, metastatic renal cell carcinoma (mRCC) treatment underwent significant advancement that resulted in an unprecedented improvement in the prognosis of this disease. This review will provide an updated review of currently approved treatment options, namely antiangiogenic and immunotherapy, as well as treatment guideline recommended by the National Comprehensive Cancer Network (NCCN). We will summarize studies ongoing in determining prognostic and predictive biomarkers in maximizing therapeutic benefit in the treatment of this disease. Lastly, we will discuss promising agents in clinical testing.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
晚期肾细胞癌的最新管理、生物标志物和未来方向。
在过去的十年中,转移性肾细胞癌(mRCC)的治疗取得了重大进展,导致这种疾病的预后得到了前所未有的改善。本综述将提供当前批准的治疗方案的最新综述,即抗血管生成和免疫治疗,以及国家综合癌症网络(NCCN)推荐的治疗指南。我们将总结正在进行的确定预后和预测生物标志物的研究,以最大限度地提高这种疾病的治疗效益。最后,我们将讨论在临床试验中有前景的药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
An update on current management of advanced renal cell cancer, biomarkers, and future directions. An update on current management of advanced renal cell cancer, biomarkers, and future directions.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1